Solasia Pharma K.K. (TYO:4597)

31.03% (1Y)

Market Cap	8.29B
Revenue (ttm)	330.00M
Net Income (ttm)	-1.92B
Shares Out	218.05M
EPS (ttm)	-9.17
PE Ratio	n/a
Forward PE	n/a
Dividend	n/a
Ex-Dividend Date	n/a

Volume	20,223,700
Average Volume	19,579,680
Open	39.00
Previous Close	40.00
Day's Range	37.00 - 42.00
52-Week Range	27.00 - 70.00
Beta	1.12
RSI	55.91
Earnings Date	Aug 13, 2025

About Solasia Pharma K.K.

Solasia Pharma K.K. engages in the development and marketing of oncology drugs in Japan and other Asian countries. The company offers Episil, an oral liquid for oral mucositis/stomatitis; and DARVIAS, an antineoplastic agent injection for relapsed or refractory peripheral T-cell lymphoma. It also develops Sancuso for chemotherapy induced nausea and vomiting; SP-04, which is in preclinical trial development to treat chemotherapy peripheral neuropathy; and SP-05 for the treatment of colorectal cancer. The company was founded in 2006 and is based ...

• Industry: Drug Manufacturers - Specialty & Generic
• Sector: Healthcare
• Founded: 2006
• Employees: 23
• Stock Exchange: Tokyo Stock Exchange
• Ticker Symbol: 4597

Financial Performance

In 2024, Solasia Pharma K.K.'s revenue was 316.00 million, a decrease of -48.78% compared to the previous year's 617.00 million. Losses were -1.94 billion, 74.6% more than in 2023.